Sex: U
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: CONFIRMED COVID-19 INFECTION; This spontaneous report was received from literature. This report concerned multiple patients (3 females and 5 male) of above 18 year's age and unspecified race and ethnicity. The objective of this study was to describe the vaccine breakthrough cases and their outcomes compared to unvaccinated COVID-19 cases, we analyzed and compared all consecutive patients, with or without prior vaccination, who were admitted to our hospital network due to COVID-19 from JAN-2021 to APR-2021. The patient's height, and weight were not reported. The patient's concurrent conditions included: congestive heart failure, cardiac arrhythmias, hypertension, chronic pulmonary disease, diabetes, renal failure, liver disease, obesity, and metastatic cancer. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN and expiry: UNKNOWN) dose, 1 total, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, after vaccination, 8 patients with reverse transcription polymerase chain reaction (RT-PCR) test positive and primary diagnosis of covid-19 (confirmed covid-19 infection) were admitted into a hospital. All the patients had oxygen requirement upon admission. The patients had also used dexamethasone and remdesivir. Among the 8 patients 1 patient had tested positive within 1-7 days, 6 patients were tested positive between 8-14 days and 1 patient had tested positive between 15-21 days after vaccination. In the patients who tested positive within the first two weeks (1-14 days) after vaccination one patient was admitted in Intensive care unit (ICU), one patient required mechanical ventilation, one patient had death or discharged to hospice and one patient had died on unspecified date. It was unknown if an autopsy was performed. The outcome of ICU admission, mechanical ventilation, death, death or discharged to hospice was not reported in the remaining three patients who were tested positive between 1-14 days after vaccination and in the patient who had tested positive between 15-21 days after vaccination. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patients were died of covid-19 on an unspecified date. The author concluded that even a single dose of vaccination was associated with decreased risk of death. As of AUG-2021, 72% of the adult population has received at least one dose of the COVID vaccine, while more than 1.7 billion vaccine doses have been administered worldwide. The need for ongoing mass vaccination efforts is still of utmost importance, while vaccination in middle and low-income countries should remain an absolute priority. The outcome of covid-19 was death on an unspecified date. This report was serious (Death, Hospitalization Caused / Prolonged, and Life Threatening).; Sender's Comments: V0: 20211046629-covid-19 vaccine ad26.cov2.s-confirmed covid-19 infection. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).; Reported Cause(s) of Death: COVID-19